|
1）Onoue M, Terada T, Kobayashi M, et al. UGT1A1*6 polymorphism is most predictive of severe neutropenia induced by irinotecan in Japanese cancer patients. Int J Clin Oncol. 2009; 14: 136-42
|
|
|
|
2）Amado RG, Wolf M, Peeters M, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol. 2008; 26: 1626-34
|
|
|
|
|
|
3）Karapetis CS, Khambata-Ford S, Jonker DJ, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med. 2008; 359: 1757-65
|
|
|
|
|
|
4）Dahabreh IJ, Terasawa T, Castaldi PJ, et al. Systematic review: Anti-epidermal growth factor receptor treatment effect modification by KRAS mutations in advanced colorectal cancer. Ann Intern Med. 2011; 154: 7-49
|
|
|
|
|
|
5）Hurwitz HI, Yi J, Ince W, et al. The clinical benefit of bevacizumab in metastatic colorectal cancer is independent of K-ras mutation status: analysis of a phase III study of bevacizumab with chemotherapy in previously untreated metastatic colorectal cancer. Oncologist. 2009; 14: 22-8
|
|
|
|
|
|
6）Grothey A, Van Cutsem E, Sobrero A, et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2013; 381: 303-12
|
|
|
|
|
|
7）Chung KY, Shia J, Kemeny NE, et al. Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J Clin Oncol. 2005; 23: 1803-10
|
|
|
|
|
|
8）Peeters M, Cervantes-Ruiperez A, Strickland A, et al. Randomized phase Ⅲ study of panitumumab (pmab) with FOLFIRI versus FOLFIRI alone as second-line treatment (tx) in patients (pts) with metastatic colorectal cancer (mCRC): Analysis by tumor epidermal growth factor receptor (EGFR) staining. 2010 ASCO Abstract #3565
|
|
|
|
|
|
9）Siena S, Tabernero D, Cunningham P, et al. Randomized Phase Ⅲ study of panitumumab (pmab) with FOLFOX4 compared to FOLFOX4 alone as first-line treatment (tx) for metastatic colorectal cancer (mCRC): PRIME trial anyalysis by epidermal growth factor receptor (EGFR) tumor staining. 2010 ASCO Abstract #3566
|
|
|
|
|
|
10）Maughan TS, Adams RA, Smith CG, et al. Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. Lancet. 2011; 377: 103-14
|
|
|
|
|
|
11）De Roock W, Claes B, Bernasconi D, et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol. 2010; 11: 753-62
|
|
|
|
|
|
12）Oliner KS, Douillard J-Y, Siena S. Analysis of KRAS / NRAS and BRAF mutations in the phase 3 PRIME study of panitumumab (pmab) plus FOLFOX versus FOLFOX as 1st-line treatment (tx) for metastatic colorectal cancer (mCRC). 2013 ASCO Abstract #3511
|
|
|
|
|
|
13）Schwartzberg LS, Rivera F, Karthaus M, et al. Analysis of KRAS / NRAS mutations in PEAK: a randomized phase 2 study of FOLFOX6 + panitumumab or bevacizumab as 1st-line treatment for wild type (WT) KRAS (exon 2) metastatic colorectal cancer (mCRC). 2013 ASCO Abstract #3631
|
|
|
|
|
|
14）Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011; 364: 2507-16
|
|
|
|
|
|
15）Flaherty KT, Infante JR, Daud A, et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med. 2012; 367: 1694-703
|
|
|
|
|
|
16）Corcoran RB, Ebi H, Turke AB, et al. EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib. Cancer Discov. 2012; 2: 227-35
|
|
|
|
|
|
17）Prahallad A, Sun C, Huang S, et al. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature. 2012; 483: 100-3
|
|
|
|
|
|
18）Wang ZH, Gao QY, Fang JY. Loss of PTEN expression as a predictor of resistance to anti-EGFR monoclonal therapy in metastatic colorectal cancer: evidence from retrospective studies. Cancer Chemother Pharmacol. 2012; 69: 1647-55
|
|
|
|
|
|
19）Jayson GC, de Haas S, Delmar P, et al. Evaluation of plasma VEGFA as a potential predictive pan-tumour biomarker for bevacizumab. 2011 European Multidisciplinary Cancer Congress. Abstract 804
|
|
|
|
|
|
20）Draft Guidance for Industry and Food and Drug Administration Staff. In Vitro Companion Diagnostic Devices, U.S. Department of Health and Human Services, Food and Drug Administration, Center for Devices and Radiological Health, Center for Biologics Evaluation and Research, Center for Drug Evaluation and Research 2011 July 14
|
|
|
|
|